Myostatin Overexpression and Smad Pathway in Detrusor Derived from Pediatric Patients with End-Stage Lower Urinary Tract Dysfunction

Cell therapies and tissue engineering approaches using smooth muscle cells (SMCs) may provide treatment alternatives for end-stage lower urinary tract dysfunction (ESLUTD). Myostatin, a negative regulator of muscle mass, is a promising target to improve muscle function through tissue engineering. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Salemi, Souzan, Schori, Larissa J., Gerwinn, Tim, Horst, Maya, Eberli, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003571/
https://www.ncbi.nlm.nih.gov/pubmed/36901894
http://dx.doi.org/10.3390/ijms24054462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003571/
https://www.ncbi.nlm.nih.gov/pubmed/36901894
http://dx.doi.org/10.3390/ijms24054462

Ejemplares similares